| Lizenz: Creative Commons Namensnennung 4.0 International PDF - Veröffentlichte Version (853kB) |
- URN zum Zitieren dieses Dokuments:
- urn:nbn:de:bvb:355-epub-439784
- DOI zum Zitieren dieses Dokuments:
- 10.5283/epub.43978
Zusammenfassung
Alemtuzumab (anti-CD52 mAb) leads to a long-lasting disease activity suppression in patients with relapsing forms of multiple sclerosis (MS). In this study, we examined the change of the immune cell repertoire and the cellular reactivity after treatment with alemtuzumab. We analyzed the number of IFN-gamma-secreting cells in presence of several peptides which had been eluted from the central ...
Nur für Besitzer und Autoren: Kontrollseite des Eintrags
Downloadstatistik